{
    "clinical_study": {
        "@rank": "50370", 
        "arm_group": [
            {
                "arm_group_label": "0.5% ivermectin cream", 
                "arm_group_type": "Experimental", 
                "description": "Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement."
            }, 
            {
                "arm_group_label": "vehicle cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether 0.5% ivermectin cream is effective in the\n      treatment of demodicidosis (including papulopustular rosacea)"
        }, 
        "brief_title": "Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis", 
        "condition": [
            "Demodex", 
            "Demodicidosis", 
            "Topical Ivermectin"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subjects with clinical and laboratory diagnosis of demodicidosis with symmetrical\n             facial eruption who are willing to comply with study requirements\n\n        Exclusion Criteria:\n\n          -  known hypersensitivity to ivermectin.\n\n          -  pregnancy\n\n          -  immunodeficiency such as HIV or immunosuppressive therapy\n\n          -  concomitant use of systemic antibiotics or steroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036229", 
            "org_study_id": "topical ivermectin, demodex"
        }, 
        "intervention": {
            "arm_group_label": [
                "0.5% ivermectin cream", 
                "vehicle cream"
            ], 
            "description": "Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.", 
            "intervention_name": "ivermectin cream 0.5%", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ivermectin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "demodex", 
            "demodicidosis", 
            "rosacea", 
            "ivermectin"
        ], 
        "lastchanged_date": "January 12, 2014", 
        "location": {
            "contact": {
                "last_name": "Rina Segal, MD", 
                "phone": "972505206134"
            }, 
            "facility": {
                "address": {
                    "city": "Petah-Tiqva", 
                    "country": "Israel"
                }, 
                "name": "RabinMC, Dermatology dept."
            }, 
            "investigator": {
                "last_name": "Rina Segal, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "a Randomised, Double Blind, Placebo Controlled, Half- Face Study to Evaluate the Effect of Topical Ivermectin Cream 0.5% on Demodicidosis", 
        "overall_contact": {
            "email": "rinas3@clalit.org.il", 
            "last_name": "Rina Segal, MD", 
            "phone": "972505206134"
        }, 
        "overall_official": {
            "affiliation": "Rabin Medical Center", 
            "last_name": "Rina Segal, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "A decrease in mite density in skin surface biopsy after treatment with topical ivermectin (\u22645 mites/cm2   for skin lesions).", 
            "safety_issue": "No", 
            "time_frame": "5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036229"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rabin Medical Center", 
            "investigator_full_name": "Rina Segal", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical improvement will be assessed by objective evaluation of erythema, dryness, scaling, roughness, and/or papules/pustules in skin lesions and subjective evaluation of itch and dryness.", 
                "measure": "Clinical improvement", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "dermoscopic demodicidosis features:\nnumber of demodex tails\ndemodex follicular openings\nreticular dilated vessels.", 
                "measure": "A comparable dermoscopic improvement in the demodicidosis features", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }
        ], 
        "source": "Rabin Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rabin Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}